Kimelman & Baird, LLC Gilead Sciences, Inc. Transaction History
Kimelman & Baird, LLC
- $1.21 Trillion
- Q2 2024
A detailed history of Kimelman & Baird, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Kimelman & Baird, LLC holds 200 shares of GILD stock, worth $16,778. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200Holding current value
$16,778% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
1,879Shares Held
1.02BCall Options Held
12MPut Options Held
8.96M-
Black Rock Inc. New York, NY121MShares$10.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$9.67 Billion0.15% of portfolio
-
Capital World Investors Los Angeles, CA76.2MShares$6.4 Billion0.88% of portfolio
-
Capital Research Global Investors Los Angeles, CA60.4MShares$5.07 Billion0.94% of portfolio
-
State Street Corp Boston, MA59.3MShares$4.98 Billion0.18% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $105B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...